🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million new cases each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in close succession. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Outcomes and Global Access

Based on results published in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This puts it on an equal footing with the typical regimen, which combines an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Doctors treating patients have shared optimism. The availability of a one-pill regimen like this is described as a "revolutionary step" for public health efforts. This is considered essential to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.